Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a ...
Upfront PSMA PET imaging detects hidden metastases in early prostate cancer, altering treatment plans in up to one-third of ...
Cribriform-positive morphology was associated with a 3.6-fold higher risk for metastasis in patients with prostate cancer, and radiotherapy with neoadjuvant androgen deprivation therapy (ADT) was ...
A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a ...
Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a ...
SurvivorNet on MSN
Exciting new option for advanced prostate cancer: FDA approves Pluvicto earlier for PSMA-positive metastatic hormone-sensitive disease
The FDA has expanded Pluvicto’s approval, allowing its use earlier in treatment for PSMA‑positive metastatic ...
A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment intensification can meaningfully improve survival for patients with ...
Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient populationPSMAddition updated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results